nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCB1—colon cancer	0.264	1	CbGaD
Buprenorphine—UGT1A9—Irinotecan—colon cancer	0.0951	0.164	CbGbCtD
Buprenorphine—CYP2A6—Fluorouracil—colon cancer	0.0443	0.0764	CbGbCtD
Buprenorphine—ABCG2—Irinotecan—colon cancer	0.0428	0.0737	CbGbCtD
Buprenorphine—ABCG2—Fluorouracil—colon cancer	0.041	0.0707	CbGbCtD
Buprenorphine—ABCG2—Vincristine—colon cancer	0.0374	0.0644	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0316	0.0544	CbGbCtD
Buprenorphine—CYP3A7—Irinotecan—colon cancer	0.0316	0.0544	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.0276	0.0476	CbGbCtD
Buprenorphine—CYP3A7—Vincristine—colon cancer	0.0276	0.0476	CbGbCtD
Buprenorphine—CYP2C9—Capecitabine—colon cancer	0.0257	0.0443	CbGbCtD
Buprenorphine—CYP3A5—Irinotecan—colon cancer	0.0237	0.0408	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—colon cancer	0.0226	0.039	CbGbCtD
Buprenorphine—CYP2C8—Fluorouracil—colon cancer	0.0219	0.0377	CbGbCtD
Buprenorphine—CYP3A5—Vincristine—colon cancer	0.0207	0.0357	CbGbCtD
Buprenorphine—CYP1A2—Fluorouracil—colon cancer	0.0169	0.0292	CbGbCtD
Buprenorphine—ABCB1—Irinotecan—colon cancer	0.0154	0.0266	CbGbCtD
Buprenorphine—CYP2C9—Fluorouracil—colon cancer	0.0152	0.0263	CbGbCtD
Buprenorphine—ABCB1—Vincristine—colon cancer	0.0135	0.0232	CbGbCtD
Buprenorphine—CYP3A4—Irinotecan—colon cancer	0.00924	0.0159	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—colon cancer	0.00816	0.0141	CbGbCtD
Buprenorphine—CYP3A4—Vincristine—colon cancer	0.00807	0.0139	CbGbCtD
Buprenorphine—OPRL1—lymphoid tissue—colon cancer	0.00126	0.0805	CbGeAlD
Buprenorphine—UGT1A9—renal system—colon cancer	0.000986	0.0632	CbGeAlD
Buprenorphine—UGT1A9—digestive system—colon cancer	0.000809	0.0518	CbGeAlD
Buprenorphine—OPRD1—renal system—colon cancer	0.000779	0.0499	CbGeAlD
Buprenorphine—OPRL1—lymph node—colon cancer	0.000709	0.0454	CbGeAlD
Buprenorphine—CYP2C18—digestive system—colon cancer	0.000707	0.0453	CbGeAlD
Buprenorphine—CYP2C18—vagina—colon cancer	0.000624	0.04	CbGeAlD
Buprenorphine—UGT1A9—liver—colon cancer	0.000602	0.0386	CbGeAlD
Buprenorphine—CYP2C18—liver—colon cancer	0.000527	0.0337	CbGeAlD
Buprenorphine—CYP3A7—liver—colon cancer	0.000501	0.0321	CbGeAlD
Buprenorphine—CYP3A7-CYP3A51P—liver—colon cancer	0.000426	0.0273	CbGeAlD
Buprenorphine—CYP2A6—vagina—colon cancer	0.000413	0.0264	CbGeAlD
Buprenorphine—Naltrexone—ABCB1—colon cancer	0.000383	0.578	CrCbGaD
Buprenorphine—CYP2A6—liver—colon cancer	0.000348	0.0223	CbGeAlD
Buprenorphine—ABCB1—blood vessel—colon cancer	0.00034	0.0217	CbGeAlD
Buprenorphine—CYP2C8—renal system—colon cancer	0.00032	0.0205	CbGeAlD
Buprenorphine—CYP2C19—digestive system—colon cancer	0.0003	0.0192	CbGeAlD
Buprenorphine—CYP1A2—renal system—colon cancer	0.000299	0.0192	CbGeAlD
Buprenorphine—CYP3A5—renal system—colon cancer	0.000289	0.0185	CbGeAlD
Buprenorphine—Naloxone—ABCB1—colon cancer	0.00028	0.422	CrCbGaD
Buprenorphine—CYP2C19—vagina—colon cancer	0.000265	0.017	CbGeAlD
Buprenorphine—Weight decreased—Capecitabine—colon cancer	0.000259	0.00201	CcSEcCtD
Buprenorphine—Hypertension—Irinotecan—colon cancer	0.000257	0.002	CcSEcCtD
Buprenorphine—Infestation—Capecitabine—colon cancer	0.000255	0.00198	CcSEcCtD
Buprenorphine—Infestation NOS—Capecitabine—colon cancer	0.000255	0.00198	CcSEcCtD
Buprenorphine—Depression—Capecitabine—colon cancer	0.000254	0.00198	CcSEcCtD
Buprenorphine—Lethargy—Methotrexate—colon cancer	0.000252	0.00196	CcSEcCtD
Buprenorphine—Discomfort—Irinotecan—colon cancer	0.000251	0.00195	CcSEcCtD
Buprenorphine—Oedema—Vincristine—colon cancer	0.00025	0.00194	CcSEcCtD
Buprenorphine—Anaphylactic shock—Vincristine—colon cancer	0.00025	0.00194	CcSEcCtD
Buprenorphine—Infection—Vincristine—colon cancer	0.000248	0.00193	CcSEcCtD
Buprenorphine—Urinary tract infection—Capecitabine—colon cancer	0.000248	0.00193	CcSEcCtD
Buprenorphine—Conjunctivitis—Capecitabine—colon cancer	0.000248	0.00193	CcSEcCtD
Buprenorphine—Convulsion—Fluorouracil—colon cancer	0.000247	0.00192	CcSEcCtD
Buprenorphine—Osteoarthritis—Methotrexate—colon cancer	0.000247	0.00192	CcSEcCtD
Buprenorphine—CYP1A2—digestive system—colon cancer	0.000245	0.0157	CbGeAlD
Buprenorphine—Confusional state—Irinotecan—colon cancer	0.000245	0.00191	CcSEcCtD
Buprenorphine—Nervous system disorder—Vincristine—colon cancer	0.000245	0.0019	CcSEcCtD
Buprenorphine—Oedema—Irinotecan—colon cancer	0.000243	0.00189	CcSEcCtD
Buprenorphine—Anaphylactic shock—Irinotecan—colon cancer	0.000243	0.00189	CcSEcCtD
Buprenorphine—Myalgia—Fluorouracil—colon cancer	0.000243	0.00189	CcSEcCtD
Buprenorphine—Chest pain—Fluorouracil—colon cancer	0.000243	0.00189	CcSEcCtD
Buprenorphine—Infection—Irinotecan—colon cancer	0.000242	0.00188	CcSEcCtD
Buprenorphine—Hyperhidrosis—Vincristine—colon cancer	0.000241	0.00188	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Capecitabine—colon cancer	0.000241	0.00188	CcSEcCtD
Buprenorphine—Discomfort—Fluorouracil—colon cancer	0.00024	0.00187	CcSEcCtD
Buprenorphine—Shock—Irinotecan—colon cancer	0.000239	0.00186	CcSEcCtD
Buprenorphine—Nervous system disorder—Irinotecan—colon cancer	0.000238	0.00185	CcSEcCtD
Buprenorphine—Anorexia—Vincristine—colon cancer	0.000238	0.00185	CcSEcCtD
Buprenorphine—CYP3A5—digestive system—colon cancer	0.000237	0.0152	CbGeAlD
Buprenorphine—Hyperhidrosis—Irinotecan—colon cancer	0.000235	0.00183	CcSEcCtD
Buprenorphine—ABCG2—bone marrow—colon cancer	0.000235	0.0151	CbGeAlD
Buprenorphine—Confusional state—Fluorouracil—colon cancer	0.000235	0.00183	CcSEcCtD
Buprenorphine—Mood swings—Methotrexate—colon cancer	0.000234	0.00182	CcSEcCtD
Buprenorphine—Hypotension—Vincristine—colon cancer	0.000233	0.00181	CcSEcCtD
Buprenorphine—Bradycardia—Capecitabine—colon cancer	0.000233	0.00181	CcSEcCtD
Buprenorphine—CYP2C9—digestive system—colon cancer	0.000233	0.0149	CbGeAlD
Buprenorphine—Anaphylactic shock—Fluorouracil—colon cancer	0.000233	0.00181	CcSEcCtD
Buprenorphine—Oedema—Fluorouracil—colon cancer	0.000233	0.00181	CcSEcCtD
Buprenorphine—Anorexia—Irinotecan—colon cancer	0.000232	0.0018	CcSEcCtD
Buprenorphine—CYP2C8—vagina—colon cancer	0.000232	0.0148	CbGeAlD
Buprenorphine—Infection—Fluorouracil—colon cancer	0.000231	0.0018	CcSEcCtD
Buprenorphine—Rhinitis—Capecitabine—colon cancer	0.00023	0.00179	CcSEcCtD
Buprenorphine—Nervous system disorder—Fluorouracil—colon cancer	0.000228	0.00178	CcSEcCtD
Buprenorphine—Hypoaesthesia—Capecitabine—colon cancer	0.000228	0.00177	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000228	0.00177	CcSEcCtD
Buprenorphine—Pharyngitis—Capecitabine—colon cancer	0.000227	0.00177	CcSEcCtD
Buprenorphine—Tachycardia—Fluorouracil—colon cancer	0.000227	0.00177	CcSEcCtD
Buprenorphine—Hypotension—Irinotecan—colon cancer	0.000227	0.00177	CcSEcCtD
Buprenorphine—Urinary tract disorder—Capecitabine—colon cancer	0.000226	0.00176	CcSEcCtD
Buprenorphine—Insomnia—Vincristine—colon cancer	0.000226	0.00176	CcSEcCtD
Buprenorphine—Oedema peripheral—Capecitabine—colon cancer	0.000226	0.00175	CcSEcCtD
Buprenorphine—ABCG2—vagina—colon cancer	0.000225	0.0144	CbGeAlD
Buprenorphine—Connective tissue disorder—Capecitabine—colon cancer	0.000225	0.00175	CcSEcCtD
Buprenorphine—Urethral disorder—Capecitabine—colon cancer	0.000225	0.00175	CcSEcCtD
Buprenorphine—Paraesthesia—Vincristine—colon cancer	0.000224	0.00174	CcSEcCtD
Buprenorphine—CYP2C19—liver—colon cancer	0.000224	0.0143	CbGeAlD
Buprenorphine—Breast disorder—Methotrexate—colon cancer	0.000223	0.00173	CcSEcCtD
Buprenorphine—Anorexia—Fluorouracil—colon cancer	0.000222	0.00173	CcSEcCtD
Buprenorphine—Visual impairment—Capecitabine—colon cancer	0.000221	0.00172	CcSEcCtD
Buprenorphine—Insomnia—Irinotecan—colon cancer	0.00022	0.00171	CcSEcCtD
Buprenorphine—Paraesthesia—Irinotecan—colon cancer	0.000218	0.0017	CcSEcCtD
Buprenorphine—Hypotension—Fluorouracil—colon cancer	0.000218	0.00169	CcSEcCtD
Buprenorphine—Decreased appetite—Vincristine—colon cancer	0.000217	0.00169	CcSEcCtD
Buprenorphine—Dyspnoea—Irinotecan—colon cancer	0.000217	0.00169	CcSEcCtD
Buprenorphine—CYP3A4—renal system—colon cancer	0.000217	0.0139	CbGeAlD
Buprenorphine—Somnolence—Irinotecan—colon cancer	0.000216	0.00168	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Vincristine—colon cancer	0.000216	0.00168	CcSEcCtD
Buprenorphine—Fatigue—Vincristine—colon cancer	0.000215	0.00167	CcSEcCtD
Buprenorphine—Eye disorder—Capecitabine—colon cancer	0.000214	0.00166	CcSEcCtD
Buprenorphine—Dyspepsia—Irinotecan—colon cancer	0.000214	0.00166	CcSEcCtD
Buprenorphine—Tinnitus—Capecitabine—colon cancer	0.000214	0.00166	CcSEcCtD
Buprenorphine—Pain—Vincristine—colon cancer	0.000214	0.00166	CcSEcCtD
Buprenorphine—Constipation—Vincristine—colon cancer	0.000214	0.00166	CcSEcCtD
Buprenorphine—CYP2D6—renal system—colon cancer	0.000213	0.0137	CbGeAlD
Buprenorphine—Asthma—Methotrexate—colon cancer	0.000213	0.00166	CcSEcCtD
Buprenorphine—Flushing—Capecitabine—colon cancer	0.000213	0.00165	CcSEcCtD
Buprenorphine—Cardiac disorder—Capecitabine—colon cancer	0.000213	0.00165	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000212	0.00165	CcSEcCtD
Buprenorphine—Decreased appetite—Irinotecan—colon cancer	0.000211	0.00164	CcSEcCtD
Buprenorphine—Insomnia—Fluorouracil—colon cancer	0.000211	0.00164	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Irinotecan—colon cancer	0.00021	0.00163	CcSEcCtD
Buprenorphine—Fatigue—Irinotecan—colon cancer	0.00021	0.00163	CcSEcCtD
Buprenorphine—Paraesthesia—Fluorouracil—colon cancer	0.000209	0.00163	CcSEcCtD
Buprenorphine—CYP3A5—vagina—colon cancer	0.000209	0.0134	CbGeAlD
Buprenorphine—Pain—Irinotecan—colon cancer	0.000208	0.00162	CcSEcCtD
Buprenorphine—Constipation—Irinotecan—colon cancer	0.000208	0.00162	CcSEcCtD
Buprenorphine—Angiopathy—Capecitabine—colon cancer	0.000208	0.00162	CcSEcCtD
Buprenorphine—Dyspnoea—Fluorouracil—colon cancer	0.000208	0.00161	CcSEcCtD
Buprenorphine—Somnolence—Fluorouracil—colon cancer	0.000207	0.00161	CcSEcCtD
Buprenorphine—Immune system disorder—Capecitabine—colon cancer	0.000207	0.00161	CcSEcCtD
Buprenorphine—Mediastinal disorder—Capecitabine—colon cancer	0.000206	0.00161	CcSEcCtD
Buprenorphine—Chills—Capecitabine—colon cancer	0.000206	0.0016	CcSEcCtD
Buprenorphine—Dyspepsia—Fluorouracil—colon cancer	0.000205	0.00159	CcSEcCtD
Buprenorphine—Abdominal discomfort—Methotrexate—colon cancer	0.000204	0.00159	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Vincristine—colon cancer	0.000204	0.00159	CcSEcCtD
Buprenorphine—ABCB1—embryo—colon cancer	0.000203	0.013	CbGeAlD
Buprenorphine—Decreased appetite—Fluorouracil—colon cancer	0.000202	0.00157	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000201	0.00156	CcSEcCtD
Buprenorphine—Mental disorder—Capecitabine—colon cancer	0.000201	0.00156	CcSEcCtD
Buprenorphine—Feeling abnormal—Irinotecan—colon cancer	0.0002	0.00156	CcSEcCtD
Buprenorphine—Erythema—Capecitabine—colon cancer	0.000199	0.00155	CcSEcCtD
Buprenorphine—Malnutrition—Capecitabine—colon cancer	0.000199	0.00155	CcSEcCtD
Buprenorphine—Pain—Fluorouracil—colon cancer	0.000199	0.00155	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Irinotecan—colon cancer	0.000199	0.00155	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Methotrexate—colon cancer	0.000198	0.00154	CcSEcCtD
Buprenorphine—Abdominal pain—Vincristine—colon cancer	0.000197	0.00153	CcSEcCtD
Buprenorphine—Body temperature increased—Vincristine—colon cancer	0.000197	0.00153	CcSEcCtD
Buprenorphine—Flatulence—Capecitabine—colon cancer	0.000197	0.00153	CcSEcCtD
Buprenorphine—CYP2C8—liver—colon cancer	0.000195	0.0125	CbGeAlD
Buprenorphine—Dysgeusia—Capecitabine—colon cancer	0.000195	0.00152	CcSEcCtD
Buprenorphine—Back pain—Capecitabine—colon cancer	0.000193	0.0015	CcSEcCtD
Buprenorphine—Abdominal pain—Irinotecan—colon cancer	0.000192	0.00149	CcSEcCtD
Buprenorphine—Body temperature increased—Irinotecan—colon cancer	0.000192	0.00149	CcSEcCtD
Buprenorphine—Feeling abnormal—Fluorouracil—colon cancer	0.000192	0.00149	CcSEcCtD
Buprenorphine—Muscle spasms—Capecitabine—colon cancer	0.000192	0.00149	CcSEcCtD
Buprenorphine—Infestation—Methotrexate—colon cancer	0.00019	0.00148	CcSEcCtD
Buprenorphine—Infestation NOS—Methotrexate—colon cancer	0.00019	0.00148	CcSEcCtD
Buprenorphine—ABCG2—liver—colon cancer	0.00019	0.0122	CbGeAlD
Buprenorphine—Depression—Methotrexate—colon cancer	0.000189	0.00147	CcSEcCtD
Buprenorphine—Vision blurred—Capecitabine—colon cancer	0.000188	0.00146	CcSEcCtD
Buprenorphine—Tremor—Capecitabine—colon cancer	0.000187	0.00145	CcSEcCtD
Buprenorphine—Ill-defined disorder—Capecitabine—colon cancer	0.000185	0.00144	CcSEcCtD
Buprenorphine—Urticaria—Fluorouracil—colon cancer	0.000185	0.00144	CcSEcCtD
Buprenorphine—Conjunctivitis—Methotrexate—colon cancer	0.000185	0.00144	CcSEcCtD
Buprenorphine—Body temperature increased—Fluorouracil—colon cancer	0.000184	0.00143	CcSEcCtD
Buprenorphine—Hypersensitivity—Vincristine—colon cancer	0.000184	0.00143	CcSEcCtD
Buprenorphine—CYP1A2—liver—colon cancer	0.000183	0.0117	CbGeAlD
Buprenorphine—Sweating—Methotrexate—colon cancer	0.000182	0.00142	CcSEcCtD
Buprenorphine—Malaise—Capecitabine—colon cancer	0.00018	0.0014	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Methotrexate—colon cancer	0.00018	0.0014	CcSEcCtD
Buprenorphine—Vertigo—Capecitabine—colon cancer	0.000179	0.00139	CcSEcCtD
Buprenorphine—Hypersensitivity—Irinotecan—colon cancer	0.000179	0.00139	CcSEcCtD
Buprenorphine—Asthenia—Vincristine—colon cancer	0.000179	0.00139	CcSEcCtD
Buprenorphine—Syncope—Capecitabine—colon cancer	0.000179	0.00139	CcSEcCtD
Buprenorphine—CYP3A4—digestive system—colon cancer	0.000178	0.0114	CbGeAlD
Buprenorphine—CYP3A5—liver—colon cancer	0.000176	0.0113	CbGeAlD
Buprenorphine—Palpitations—Capecitabine—colon cancer	0.000176	0.00137	CcSEcCtD
Buprenorphine—Loss of consciousness—Capecitabine—colon cancer	0.000175	0.00136	CcSEcCtD
Buprenorphine—CYP2D6—digestive system—colon cancer	0.000175	0.0112	CbGeAlD
Buprenorphine—Asthenia—Irinotecan—colon cancer	0.000174	0.00136	CcSEcCtD
Buprenorphine—Cough—Capecitabine—colon cancer	0.000174	0.00135	CcSEcCtD
Buprenorphine—CYP2C9—liver—colon cancer	0.000174	0.0111	CbGeAlD
Buprenorphine—Hypertension—Capecitabine—colon cancer	0.000172	0.00134	CcSEcCtD
Buprenorphine—Hypersensitivity—Fluorouracil—colon cancer	0.000172	0.00133	CcSEcCtD
Buprenorphine—Diarrhoea—Vincristine—colon cancer	0.000171	0.00133	CcSEcCtD
Buprenorphine—Chest pain—Capecitabine—colon cancer	0.00017	0.00132	CcSEcCtD
Buprenorphine—Arthralgia—Capecitabine—colon cancer	0.00017	0.00132	CcSEcCtD
Buprenorphine—Myalgia—Capecitabine—colon cancer	0.00017	0.00132	CcSEcCtD
Buprenorphine—Pharyngitis—Methotrexate—colon cancer	0.000169	0.00132	CcSEcCtD
Buprenorphine—Anxiety—Capecitabine—colon cancer	0.000169	0.00132	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000169	0.00131	CcSEcCtD
Buprenorphine—Urinary tract disorder—Methotrexate—colon cancer	0.000168	0.00131	CcSEcCtD
Buprenorphine—Discomfort—Capecitabine—colon cancer	0.000168	0.0013	CcSEcCtD
Buprenorphine—Urethral disorder—Methotrexate—colon cancer	0.000167	0.0013	CcSEcCtD
Buprenorphine—Diarrhoea—Irinotecan—colon cancer	0.000166	0.00129	CcSEcCtD
Buprenorphine—Dry mouth—Capecitabine—colon cancer	0.000166	0.00129	CcSEcCtD
Buprenorphine—ABCB1—epithelium—colon cancer	0.000165	0.0106	CbGeAlD
Buprenorphine—Dizziness—Vincristine—colon cancer	0.000165	0.00128	CcSEcCtD
Buprenorphine—Pruritus—Fluorouracil—colon cancer	0.000165	0.00128	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—colon cancer	0.000164	0.00128	CcSEcCtD
Buprenorphine—Confusional state—Capecitabine—colon cancer	0.000164	0.00128	CcSEcCtD
Buprenorphine—Oedema—Capecitabine—colon cancer	0.000163	0.00127	CcSEcCtD
Buprenorphine—Infection—Capecitabine—colon cancer	0.000162	0.00126	CcSEcCtD
Buprenorphine—Dizziness—Irinotecan—colon cancer	0.000161	0.00125	CcSEcCtD
Buprenorphine—Shock—Capecitabine—colon cancer	0.00016	0.00125	CcSEcCtD
Buprenorphine—Nervous system disorder—Capecitabine—colon cancer	0.00016	0.00124	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—colon cancer	0.000159	0.00124	CcSEcCtD
Buprenorphine—Diarrhoea—Fluorouracil—colon cancer	0.000159	0.00124	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—colon cancer	0.000159	0.00124	CcSEcCtD
Buprenorphine—Tachycardia—Capecitabine—colon cancer	0.000159	0.00124	CcSEcCtD
Buprenorphine—Vomiting—Vincristine—colon cancer	0.000159	0.00123	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—colon cancer	0.000158	0.00123	CcSEcCtD
Buprenorphine—Skin disorder—Capecitabine—colon cancer	0.000158	0.00123	CcSEcCtD
Buprenorphine—Rash—Vincristine—colon cancer	0.000157	0.00122	CcSEcCtD
Buprenorphine—Hyperhidrosis—Capecitabine—colon cancer	0.000157	0.00122	CcSEcCtD
Buprenorphine—Dermatitis—Vincristine—colon cancer	0.000157	0.00122	CcSEcCtD
Buprenorphine—Headache—Vincristine—colon cancer	0.000156	0.00122	CcSEcCtD
Buprenorphine—Anorexia—Capecitabine—colon cancer	0.000155	0.00121	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—colon cancer	0.000155	0.0012	CcSEcCtD
Buprenorphine—Vomiting—Irinotecan—colon cancer	0.000155	0.0012	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—colon cancer	0.000154	0.0012	CcSEcCtD
Buprenorphine—Dizziness—Fluorouracil—colon cancer	0.000154	0.0012	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—colon cancer	0.000154	0.0012	CcSEcCtD
Buprenorphine—Rash—Irinotecan—colon cancer	0.000153	0.00119	CcSEcCtD
Buprenorphine—ABCB1—renal system—colon cancer	0.000153	0.00982	CbGeAlD
Buprenorphine—Dermatitis—Irinotecan—colon cancer	0.000153	0.00119	CcSEcCtD
Buprenorphine—Chills—Methotrexate—colon cancer	0.000153	0.00119	CcSEcCtD
Buprenorphine—Headache—Irinotecan—colon cancer	0.000152	0.00118	CcSEcCtD
Buprenorphine—Hypotension—Capecitabine—colon cancer	0.000152	0.00118	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—colon cancer	0.000149	0.00116	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—colon cancer	0.000148	0.00115	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—colon cancer	0.000148	0.00115	CcSEcCtD
Buprenorphine—Nausea—Vincristine—colon cancer	0.000148	0.00115	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000148	0.00115	CcSEcCtD
Buprenorphine—Vomiting—Fluorouracil—colon cancer	0.000148	0.00115	CcSEcCtD
Buprenorphine—Insomnia—Capecitabine—colon cancer	0.000147	0.00114	CcSEcCtD
Buprenorphine—Rash—Fluorouracil—colon cancer	0.000147	0.00114	CcSEcCtD
Buprenorphine—Dermatitis—Fluorouracil—colon cancer	0.000147	0.00114	CcSEcCtD
Buprenorphine—Paraesthesia—Capecitabine—colon cancer	0.000146	0.00114	CcSEcCtD
Buprenorphine—Headache—Fluorouracil—colon cancer	0.000146	0.00113	CcSEcCtD
Buprenorphine—ABCG2—lymph node—colon cancer	0.000146	0.00933	CbGeAlD
Buprenorphine—Dysgeusia—Methotrexate—colon cancer	0.000145	0.00113	CcSEcCtD
Buprenorphine—Dyspnoea—Capecitabine—colon cancer	0.000145	0.00113	CcSEcCtD
Buprenorphine—Nausea—Irinotecan—colon cancer	0.000144	0.00112	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—colon cancer	0.000144	0.00112	CcSEcCtD
Buprenorphine—Dyspepsia—Capecitabine—colon cancer	0.000143	0.00111	CcSEcCtD
Buprenorphine—Decreased appetite—Capecitabine—colon cancer	0.000141	0.0011	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000141	0.00109	CcSEcCtD
Buprenorphine—Fatigue—Capecitabine—colon cancer	0.00014	0.00109	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—colon cancer	0.00014	0.00109	CcSEcCtD
Buprenorphine—Constipation—Capecitabine—colon cancer	0.000139	0.00108	CcSEcCtD
Buprenorphine—Pain—Capecitabine—colon cancer	0.000139	0.00108	CcSEcCtD
Buprenorphine—Nausea—Fluorouracil—colon cancer	0.000138	0.00108	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—colon cancer	0.000138	0.00107	CcSEcCtD
Buprenorphine—Feeling abnormal—Capecitabine—colon cancer	0.000134	0.00104	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—colon cancer	0.000134	0.00104	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—colon cancer	0.000133	0.00104	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Capecitabine—colon cancer	0.000133	0.00103	CcSEcCtD
Buprenorphine—CYP3A4—liver—colon cancer	0.000132	0.00848	CbGeAlD
Buprenorphine—CYP2D6—liver—colon cancer	0.00013	0.00834	CbGeAlD
Buprenorphine—Cough—Methotrexate—colon cancer	0.00013	0.00101	CcSEcCtD
Buprenorphine—Urticaria—Capecitabine—colon cancer	0.000129	0.00101	CcSEcCtD
Buprenorphine—Abdominal pain—Capecitabine—colon cancer	0.000129	0.001	CcSEcCtD
Buprenorphine—Body temperature increased—Capecitabine—colon cancer	0.000129	0.001	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—colon cancer	0.000129	0.001	CcSEcCtD
Buprenorphine—ABCB1—lymphoid tissue—colon cancer	0.000127	0.00815	CbGeAlD
Buprenorphine—Myalgia—Methotrexate—colon cancer	0.000126	0.000983	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—colon cancer	0.000126	0.000983	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—colon cancer	0.000126	0.000983	CcSEcCtD
Buprenorphine—ABCB1—digestive system—colon cancer	0.000126	0.00805	CbGeAlD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000126	0.000976	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—colon cancer	0.000125	0.000971	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—colon cancer	0.000122	0.00095	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—colon cancer	0.000121	0.000942	CcSEcCtD
Buprenorphine—Infection—Methotrexate—colon cancer	0.00012	0.000936	CcSEcCtD
Buprenorphine—Hypersensitivity—Capecitabine—colon cancer	0.00012	0.000932	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—colon cancer	0.000119	0.000924	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—colon cancer	0.000118	0.000915	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—colon cancer	0.000117	0.000911	CcSEcCtD
Buprenorphine—Asthenia—Capecitabine—colon cancer	0.000117	0.000908	CcSEcCtD
Buprenorphine—ABCB1—bone marrow—colon cancer	0.000116	0.00742	CbGeAlD
Buprenorphine—Anorexia—Methotrexate—colon cancer	0.000115	0.000898	CcSEcCtD
Buprenorphine—Pruritus—Capecitabine—colon cancer	0.000115	0.000895	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—colon cancer	0.000113	0.00088	CcSEcCtD
Buprenorphine—Diarrhoea—Capecitabine—colon cancer	0.000111	0.000866	CcSEcCtD
Buprenorphine—ABCB1—vagina—colon cancer	0.000111	0.00711	CbGeAlD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00011	0.000858	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—colon cancer	0.00011	0.000852	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—colon cancer	0.000109	0.000846	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—colon cancer	0.000108	0.00084	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—colon cancer	0.000108	0.000838	CcSEcCtD
Buprenorphine—Dizziness—Capecitabine—colon cancer	0.000108	0.000837	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—colon cancer	0.000107	0.000829	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—colon cancer	0.000105	0.000819	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000105	0.000813	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—colon cancer	0.000104	0.000812	CcSEcCtD
Buprenorphine—Pain—Methotrexate—colon cancer	0.000104	0.000806	CcSEcCtD
Buprenorphine—Vomiting—Capecitabine—colon cancer	0.000103	0.000805	CcSEcCtD
Buprenorphine—Rash—Capecitabine—colon cancer	0.000103	0.000798	CcSEcCtD
Buprenorphine—Dermatitis—Capecitabine—colon cancer	0.000103	0.000797	CcSEcCtD
Buprenorphine—Headache—Capecitabine—colon cancer	0.000102	0.000793	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—colon cancer	9.98e-05	0.000776	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—colon cancer	9.91e-05	0.00077	CcSEcCtD
Buprenorphine—Nausea—Capecitabine—colon cancer	9.67e-05	0.000752	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—colon cancer	9.63e-05	0.000748	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—colon cancer	9.58e-05	0.000745	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—colon cancer	9.58e-05	0.000745	CcSEcCtD
Buprenorphine—ABCB1—liver—colon cancer	9.37e-05	0.006	CbGeAlD
Buprenorphine—Hypersensitivity—Methotrexate—colon cancer	8.93e-05	0.000694	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—colon cancer	8.69e-05	0.000676	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—colon cancer	8.57e-05	0.000667	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—colon cancer	8.29e-05	0.000645	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—colon cancer	8.01e-05	0.000623	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—colon cancer	7.7e-05	0.000599	CcSEcCtD
Buprenorphine—Rash—Methotrexate—colon cancer	7.64e-05	0.000594	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—colon cancer	7.63e-05	0.000593	CcSEcCtD
Buprenorphine—Headache—Methotrexate—colon cancer	7.59e-05	0.00059	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—colon cancer	7.2e-05	0.00056	CcSEcCtD
Buprenorphine—ABCB1—lymph node—colon cancer	7.18e-05	0.0046	CbGeAlD
Buprenorphine—ABCB1—Allograft Rejection—TGFB1—colon cancer	1.31e-05	0.0012	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	1.27e-05	0.00116	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—APC—colon cancer	1.23e-05	0.00113	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—NRAS—colon cancer	1.23e-05	0.00113	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	1.2e-05	0.0011	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ODC1—colon cancer	1.18e-05	0.00108	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CHST5—colon cancer	1.18e-05	0.00108	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	1.18e-05	0.00108	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CA7—colon cancer	1.17e-05	0.00107	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—BRAF—colon cancer	1.16e-05	0.00106	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ODC1—colon cancer	1.15e-05	0.00105	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CHST5—colon cancer	1.15e-05	0.00105	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—EGFR—colon cancer	1.12e-05	0.00103	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CHST5—colon cancer	1.08e-05	0.000991	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ODC1—colon cancer	1.08e-05	0.000991	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—PIK3CA—colon cancer	1.07e-05	0.000983	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CHST5—colon cancer	1.07e-05	0.000982	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ODC1—colon cancer	1.07e-05	0.000982	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—KRAS—colon cancer	1.06e-05	0.000971	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	1.05e-05	0.000962	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.03e-05	0.000946	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—PIK3CA—colon cancer	9.75e-06	0.000892	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ODC1—colon cancer	9.18e-06	0.000839	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CHST5—colon cancer	9.18e-06	0.000839	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—HRAS—colon cancer	9.03e-06	0.000826	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	8.94e-06	0.000818	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AKT1—colon cancer	8.78e-06	0.000803	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CASP3—colon cancer	8.69e-06	0.000795	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCND1—colon cancer	8.46e-06	0.000774	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CTNNB1—colon cancer	8.38e-06	0.000767	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ABCB1—colon cancer	8.38e-06	0.000766	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	8.3e-06	0.000759	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—TYMS—colon cancer	8.23e-06	0.000752	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CDKN1A—colon cancer	8.19e-06	0.000749	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.14e-06	0.000744	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	8.08e-06	0.000739	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	8e-06	0.000732	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AKT1—colon cancer	7.97e-06	0.000729	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	7.81e-06	0.000715	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EP300—colon cancer	7.79e-06	0.000713	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SRC—colon cancer	7.58e-06	0.000693	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	7.43e-06	0.00068	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VEGFA—colon cancer	7.38e-06	0.000675	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NRAS—colon cancer	7.29e-06	0.000667	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	7.23e-06	0.000661	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CHST5—colon cancer	7.08e-06	0.000648	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ODC1—colon cancer	7.08e-06	0.000648	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	7.04e-06	0.000644	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MYC—colon cancer	6.79e-06	0.000621	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TGFB1—colon cancer	6.77e-06	0.000619	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.77e-06	0.000619	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EGFR—colon cancer	6.64e-06	0.000607	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ABCB1—colon cancer	6.62e-06	0.000606	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TYMS—colon cancer	6.5e-06	0.000595	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	6.48e-06	0.000593	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	6.46e-06	0.000591	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	6.34e-06	0.00058	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—KRAS—colon cancer	6.27e-06	0.000574	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	5.99e-06	0.000548	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PPARG—colon cancer	5.83e-06	0.000533	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PIK3CA—colon cancer	5.76e-06	0.000527	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—FGFR3—colon cancer	5.74e-06	0.000525	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ABCB1—colon cancer	5.62e-06	0.000514	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—colon cancer	5.57e-06	0.00051	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ABCB1—colon cancer	5.57e-06	0.000509	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TYMS—colon cancer	5.52e-06	0.000505	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	5.5e-06	0.000503	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TYMS—colon cancer	5.47e-06	0.0005	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.45e-06	0.000498	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HRAS—colon cancer	5.33e-06	0.000488	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	5.32e-06	0.000487	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—APC—colon cancer	5.27e-06	0.000482	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—NRAS—colon cancer	5.27e-06	0.000482	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ABCB1—colon cancer	5.1e-06	0.000467	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FGFR3—colon cancer	5.03e-06	0.00046	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TYMS—colon cancer	5.01e-06	0.000459	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.01e-06	0.000458	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—BRAF—colon cancer	4.95e-06	0.000453	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.86e-06	0.000445	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—colon cancer	4.8e-06	0.000439	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AKT1—colon cancer	4.71e-06	0.000431	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—APC—colon cancer	4.62e-06	0.000422	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—NRAS—colon cancer	4.62e-06	0.000422	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PPARG—colon cancer	4.61e-06	0.000421	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PIK3CA—colon cancer	4.59e-06	0.000419	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—colon cancer	4.58e-06	0.000419	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—KRAS—colon cancer	4.53e-06	0.000415	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	4.49e-06	0.000411	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.43e-06	0.000405	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—BRAF—colon cancer	4.34e-06	0.000397	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.28e-06	0.000392	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FGFR3—colon cancer	4.25e-06	0.000389	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—colon cancer	4.21e-06	0.000385	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—colon cancer	4.16e-06	0.000381	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ABCB1—colon cancer	4.03e-06	0.000368	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—colon cancer	4.02e-06	0.000368	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—colon cancer	3.97e-06	0.000364	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TYMS—colon cancer	3.95e-06	0.000362	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PPARG—colon cancer	3.91e-06	0.000358	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APC—colon cancer	3.9e-06	0.000357	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NRAS—colon cancer	3.9e-06	0.000357	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PPARG—colon cancer	3.87e-06	0.000354	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—colon cancer	3.85e-06	0.000352	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.82e-06	0.00035	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—EP300—colon cancer	3.81e-06	0.000349	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.79e-06	0.000346	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—colon cancer	3.75e-06	0.000343	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP3—colon cancer	3.71e-06	0.000339	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—BRAF—colon cancer	3.67e-06	0.000336	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—colon cancer	3.65e-06	0.000334	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—colon cancer	3.62e-06	0.000331	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—colon cancer	3.61e-06	0.00033	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—colon cancer	3.58e-06	0.000327	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.56e-06	0.000326	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—colon cancer	3.56e-06	0.000325	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—colon cancer	3.55e-06	0.000325	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1A—colon cancer	3.49e-06	0.00032	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.49e-06	0.000319	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—colon cancer	3.49e-06	0.000319	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TYMS—colon cancer	3.42e-06	0.000313	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—colon cancer	3.4e-06	0.000311	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—colon cancer	3.4e-06	0.000311	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—colon cancer	3.38e-06	0.000309	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—colon cancer	3.36e-06	0.000307	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EP300—colon cancer	3.33e-06	0.000304	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—colon cancer	3.28e-06	0.0003	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—colon cancer	3.25e-06	0.000298	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SRC—colon cancer	3.23e-06	0.000296	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.18e-06	0.000291	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—colon cancer	3.17e-06	0.00029	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—colon cancer	3.15e-06	0.000288	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—colon cancer	3.14e-06	0.000287	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—colon cancer	3.11e-06	0.000285	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—colon cancer	3.11e-06	0.000285	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—colon cancer	3.09e-06	0.000282	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—colon cancer	3.07e-06	0.000281	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—colon cancer	3.06e-06	0.00028	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—colon cancer	3.06e-06	0.00028	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—colon cancer	3.05e-06	0.000279	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—colon cancer	3.01e-06	0.000276	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—colon cancer	2.98e-06	0.000273	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—colon cancer	2.98e-06	0.000273	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.98e-06	0.000273	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—colon cancer	2.92e-06	0.000267	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.9e-06	0.000265	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—colon cancer	2.9e-06	0.000265	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—colon cancer	2.89e-06	0.000264	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—colon cancer	2.86e-06	0.000262	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—colon cancer	2.86e-06	0.000261	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—colon cancer	2.84e-06	0.00026	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—colon cancer	2.84e-06	0.000259	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—colon cancer	2.83e-06	0.000259	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—colon cancer	2.82e-06	0.000258	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—colon cancer	2.81e-06	0.000257	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—colon cancer	2.8e-06	0.000256	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—colon cancer	2.79e-06	0.000256	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—colon cancer	2.79e-06	0.000255	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—colon cancer	2.78e-06	0.000254	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—colon cancer	2.76e-06	0.000253	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—colon cancer	2.75e-06	0.000252	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—colon cancer	2.73e-06	0.00025	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—colon cancer	2.68e-06	0.000245	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—colon cancer	2.68e-06	0.000245	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—colon cancer	2.65e-06	0.000242	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.64e-06	0.000241	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—colon cancer	2.59e-06	0.000237	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—colon cancer	2.56e-06	0.000234	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—colon cancer	2.54e-06	0.000232	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—colon cancer	2.53e-06	0.000232	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—colon cancer	2.53e-06	0.000232	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—colon cancer	2.52e-06	0.000231	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—colon cancer	2.49e-06	0.000227	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.48e-06	0.000227	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—colon cancer	2.46e-06	0.000225	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—colon cancer	2.46e-06	0.000225	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—colon cancer	2.43e-06	0.000222	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—colon cancer	2.42e-06	0.000222	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—colon cancer	2.4e-06	0.000219	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—colon cancer	2.38e-06	0.000218	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—colon cancer	2.38e-06	0.000218	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.35e-06	0.000215	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—colon cancer	2.35e-06	0.000215	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—colon cancer	2.33e-06	0.000213	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—colon cancer	2.32e-06	0.000213	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—colon cancer	2.31e-06	0.000211	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—colon cancer	2.3e-06	0.000211	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—colon cancer	2.28e-06	0.000208	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—colon cancer	2.23e-06	0.000204	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—colon cancer	2.2e-06	0.000202	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—colon cancer	2.17e-06	0.000198	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—colon cancer	2.16e-06	0.000197	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—colon cancer	2.15e-06	0.000196	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.15e-06	0.000196	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—colon cancer	2.14e-06	0.000196	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—colon cancer	2.11e-06	0.000193	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—colon cancer	2.1e-06	0.000192	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—colon cancer	2.09e-06	0.000191	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—colon cancer	2.01e-06	0.000184	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—colon cancer	2e-06	0.000183	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—colon cancer	1.99e-06	0.000182	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—colon cancer	1.98e-06	0.000181	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—colon cancer	1.97e-06	0.000181	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—colon cancer	1.91e-06	0.000175	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—colon cancer	1.89e-06	0.000173	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—colon cancer	1.87e-06	0.000172	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—colon cancer	1.87e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—colon cancer	1.84e-06	0.000168	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.83e-06	0.000168	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—colon cancer	1.83e-06	0.000168	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—colon cancer	1.82e-06	0.000167	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—colon cancer	1.82e-06	0.000167	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—colon cancer	1.76e-06	0.000161	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—colon cancer	1.76e-06	0.000161	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—colon cancer	1.72e-06	0.000157	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—colon cancer	1.7e-06	0.000156	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—colon cancer	1.69e-06	0.000154	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—colon cancer	1.69e-06	0.000154	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—colon cancer	1.66e-06	0.000152	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—colon cancer	1.59e-06	0.000145	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—colon cancer	1.57e-06	0.000143	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—colon cancer	1.55e-06	0.000142	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—colon cancer	1.55e-06	0.000141	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—colon cancer	1.53e-06	0.00014	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—colon cancer	1.49e-06	0.000136	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—colon cancer	1.42e-06	0.00013	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—colon cancer	1.4e-06	0.000128	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—colon cancer	1.38e-06	0.000126	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—colon cancer	1.36e-06	0.000124	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—colon cancer	1.33e-06	0.000121	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—colon cancer	1.3e-06	0.000119	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—colon cancer	1.3e-06	0.000119	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—colon cancer	1.29e-06	0.000118	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—colon cancer	1.17e-06	0.000107	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—colon cancer	1.11e-06	0.000101	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—colon cancer	1.1e-06	0.000101	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—colon cancer	1.05e-06	9.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—colon cancer	1.02e-06	9.37e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—colon cancer	1.02e-06	9.35e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—colon cancer	9.64e-07	8.82e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—colon cancer	9.59e-07	8.77e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—colon cancer	9.55e-07	8.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—colon cancer	8.56e-07	7.83e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—colon cancer	8.52e-07	7.79e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—colon cancer	8.35e-07	7.64e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—colon cancer	8.16e-07	7.47e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—colon cancer	7.87e-07	7.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—colon cancer	7.81e-07	7.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—colon cancer	6.67e-07	6.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—colon cancer	6.3e-07	5.76e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—colon cancer	5.15e-07	4.71e-05	CbGpPWpGaD
